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increased pressure for a more thorough
screening for a wide variety of neurotoxic
end points and an interpretation of the
significance of effects on the nervous sys-
tem, particularly in the context ofpremar-
ket testing and quantification ofneurotoxic
risks that could contribute to setting overall
priorities for risk reduction. This historical
overview will explain how the professional
community came to the current conception
of the problem, how methodologies have
evolved to meet the changing needs ofdeci-
sion makers, and how problem definitions
and research techniques need to change fur-
ther, both to meet future decision-making
needs and to take advantage ofopportuni-
ties to develop a fuller understanding of
neurotoxic risks.
Risk assessment is the attempt to pre-
dict the likelihood that an agent will pro-
duce adverse effects in humans, typically
from information obtained in animals.
Assessment ofriskdates from historical times,
as it became the responsibility ofauthorities
to protect its charges. However, it was not
until recent times that this responsibility
became formalized. The increase in the
number ofchemicals to which people are
exposed, the numbers ofcases ofadverse
effects ofthose exposures, the different type
ofadverse effects, and the increased precision
with which levels ofcompounds that may be
related to those effects are assayed has placed
an increased level of responsibility on the
process ofriskassessment.
Emergence of
NeurobebavioralToxicology
During the last 30 years, there has been a
sharp increase in regulatory activity by vari-
ous governmental agencies to protect the
population from toxic agents. This regula-
tory emphasis is based on several factors,
including the demonstrated causal relation-
ships between adverse health outcomes and
occupational/environmental exposures,
realization ofthe pervasive presence ofenvi-
ronmental exposures because of increased
analytical chemical capabilities, and the
concern that many chemicals in the
environment have not been tested for
potential toxicity. In the United States, at
the federal level, four regulatory agencies
have been given primary responsibility for
regulating exposures to toxic chemicals: the
U.S. Food and DrugAdministration (FDA)
(most food, drug, and cosmetic exposures),
the Occupational Safety and Health
Administration (OSHA) (workplace expo-
sures); the U.S. Environmental Protection
Agency (U.S. EPA) (air, water, pesticides,
and miscellaneous exposures to industrial
chemicals-the latter via the Toxic
Substances Control Act), and the Consumer
Product Safety Commission (CPSC) (1).
Premarket screening is generally conducted
for new food additives, drugs, pesticides,
and some industrial chemicals when there is
reason to suspect that anticipated use may
pose unreasonable risks. In addition there is
a provision for requiring testing of chemi-
cals that are already on the market in the
case ofpesticides (on reregistration) and
selected industrial chemicals. Similar
requirements are present in a number of
other countries.
Since 1975, several expert panels have
recommended that regulatory agencies
should screen chemicals for neurotoxic-
ity; many of these recommendations -
specifically stated that neurobehavioral
end points such as neurological function-
ing, motor activity and schedule-con-
trolled behavior, be used in neurotoxicity
hazard identification (2). Behavioral pro-
cedures are currently employed to evaluate
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developmental neurotoxicity of drugs in
Japan and the European Union (3), while
neurotoxicity testing protocols are being
considered by the Organization of Eco-
nomic Cooperation and Development (4).
The International Programme on Chemical
Safety (IPCS) has recommended that
chemicals be evaluated for potential neuro-
toxicity using behavioral tests (5) and is
currently sponsoring a collaborative study
to validate the use of a neurobehavioral
screening battery for the routine assessment
ofchemicals for neurotoxicity (6). Testing
guidelines for several neurobehavioral end
points, including some from developmen-
tal neurotoxicity, have been published by
the U.S. EPA (7). Neurobehavioral mea-
sures are also used in neurotoxicity hazard
identification by other regulatory agencies
in the United States, including the FDA,
OSHA and CPSC (8). Neurobehavioral
end points are frequently used in conjunc-
tion with other measures of neurotoxicity
such as neuropathology and neurochem-
istry in an integrated approach to assess
chemicals for possible neurotoxicity (7).
The development ofquantitative meth-
ods in neurobehavioral toxicity assessment
clearly has its roots in behavioral pharma-
cology. Pavlov, Skinner, and Freud each
contributed in their own way to the assess-
ment of the behavioral effects of agents,
and, as this type ofanalysis grew, behavioral
pharmacologists quickly learned the value
ofcomplete dose-effect data from pharma-
cologists. While the era of quantitative
analysis ofbehavioral pharmacology data
was ushered in by the seminal workofDews
(9), quantitative work in behavioral toxicol-
ogy closely followed. In one of the first
demonstration ofthese methods Armstrong
et al. (10) demonstrated behavioral changes
resulting from exposure to mercury vapor
using schedule-controlled behavior.
DevelopmentofMoreQuantitative
Conceptions ofRisk
Until recently, neurobehavioral end
points have primarily been used in a qual-
itative sense to determine whether chemi-
cals may produce neurotoxicity; i.e.,
hazard identification. During the last few
years, there have been attempts to develop
more quantitative descriptions of risk so
that regulatory agencies might determine
the level of exposure to a toxic chemical
that should be considered safe in a regula-
tory context and the likelihood and possi-
ble extent ofharm that might result from
exposure to the chemical at different levels
and durations.
The overwhelming majority ofcurrent
attempts to quantify risk are based on
concepts developed over 40 years ago in
which a specific number, the allowable
daily intake (ADI) is derived from experi-
mental data to determine safe levels for
regulatory purposes (11). As updated in
present usage this approach is essentially
based on finding a dose that does not pro-
duce an adverse effect in an experimental
system (the no observed adverse effect level
NOAEL) and that uses uncertainty factors
to account for considerations such as dif-
ferences between humans and animals, dif-
ferences among humans in individual
sensitivity, possible interactions between
chemicals in the diet, and various depar-
tures from ideal quality and coverage of
sensitive end points in the data base. The
ADI is intended to represent the dose rate
for a chemical (in mg/kg body weight/day)
that is likely to be without appreciable
risk ofdeleterious effects during a lifetime
ofexposure.
At the present time, risk assessment
guidelines published by the CPSC (12), and
under review by the U.S. EPA, discuss sev-
eral techniques to obtain a quantitative esti-
mate ofrisk. In spite ofthe lack offormal
risk assessment guidelines, the U.S. EPA
has used neurotoxic end points to make
regulatory decisions for a substantial num-
ber of chemicals. For example, the EPAs
Integrated Risk Information System (IRIS),
which contains information on regulatory
decisions made by the agency, indicates that
approximately 20% ofthe nearly 550 stan-
dards or advisories in the database are based
wholly or in part on neurotoxic end points.
Approximately one halfofthe neurotoxic
end points used were neurobehavioral
effects, including neurological signs, changes
in motor activity, and altered sensorimotor
function (13).
In recent years there have been
increased pressures for quantification ofrisk
levels arising from a) the desire to evaluate
the health benefits in some terms that can
be comparedwith economic costs ofregula-
tory control actions, b) priority ranking
schemes to direct agency attention to
arguably more significant problems (14,15)
and c) needs for more quantitative assess-
ments ofsignificance in the context ofeco-
logical risk assessment.
Finally, advances in our scientific under-
standing now indicate that some neurotoxic
effects in the human population may be
subtle butsignificant. Such effects include
* Reversible impairments in sensorimo-
tor function due to solvent exposures that
might contribute to industrial and automo-
bile accidents,
* Cognitive/learning deficits resulting
from developmental exposures to neurotox-
icants exposure to which cannot be entirely
eliminated, but for which some relatively
costly measures are possible for further
reduction-lead, methyl mercury, PCBs.
* Contributions to delayed and cumula-
tive neurodegenerative changes underlying
Parkinsonism, and possibly Alzheimer's dis-
ease and amyotrophic lateral sclerosis (ALS).
Current Methodologies:
Adequacies and Inadequacies
TheReference DoseApproach-The
DefaultPosition
Quantification of risk using the reference
dose (RfD) approach involves estimation of
the quantitative relationship between the
magnitude ofa response and the exposure
or dose. In the RfD model, a high dose is
usually one that produces some generalized
or systemic effects, while a low dose usually
produces no detectable response above
background [i.e., it is a no effect level
(NOEL), or a NOAEL if a judgment is
made that a particular detectable effect is
not "adverse"]. As described by Barnes and
Dourson (16), the RfD is "an estimate ofa
daily exposure to the human population
that is likely to be without appreciable risk
ofdeleterious effects during a life-time."
The RfD approach for noncancer end
points such as neurotoxicity assumes that
there is a threshold for the critical effect.
The RfD approach depends on the
selection of a critical effect or the effect
observed at the lowest dose level from a set
ofstudies on the agent. Based on the avail-
able data, a NOAEL based on the critical
effect is determined. If a NOAEL cannot
be determined, then the lowest dose at
which the critical effect is observed (the
LOAEL) is determined. To obtain an RfD,
the NOAEL is divided by a series ofuncer-
tainty factors reflecting various sources of
uncertainty in the data set.
Table 1 lists guidelines for the use
of uncertainty factors currently recom-
mended by the U.S. EPA. Examples of
uncertainty factors, which are usually fac-
tors of 10, include variation in sensitivity
within human populations, extrapolation
from animal data to humans, and less
than lifetime to lifetime exposure. In the
case where a LOAEL must be used
because a NOAEL is unavailable, another
factor of 10 is included. A modifying fac-
tor of less than 1- to 10-fold may be used
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Table 1. Guidelines forthe use of uncertainty factors in deriving reference dose (RfD).a
Standard uncertainty factors
H Human to sensitive human
A Animal to human
S Subchronic to chronic
L LOAEL to NOAEL
Modifying factor
Guideline
Use a 10-fold factorwhen extrapolating from valid experimental
results from studies using prolonged exposure to average healthy
humans. This factor is intended to accountforthe variation in
sensitivity among the members ofthe human population.
Use an additional 10-fold factorwhen extrapolating from valid
results of long-term studies on experimental animals when results
ofstudies of human exposure are not available orare inadequate.
This factor is intended to accountforthe uncertainty in extrapolating
animal data to the case of average healthy humans.
Use up to an additional 10-fold factorwhen extrapolating from less
than chronic results on experimental animals or humans when there
are no useful long-term human data. This factor is intended to
accountforthe uncertainty in extrapolating from less than chronic
NOAELs to chronic NOAELs.
Use up to an additional 10-fold factorwhen deriving an RfD from a
LOAEL instead of NOAEL. This factor is intended to account forthe
uncertainty is extrapolating from LOAELs to NOAELs.
Use professional judgment to determine another uncertainty factor
(MF) that is less than or equal to 10. The magnitude ofthe MF
depends upon the professional assessment ofscientific uncertainties
ofthe study and data base not explicitlytreated above, e.g., the
number of animals tested. The default value forthe MF is 1.
OAdapted from Barnes and Dourson (15).
to account for the incompleteness of the
data set (17).
The traditional RfD/ADI/Safety Factor
approach has several advantages:
* It is relatively straightforward to apply
and does not require complicated model
building or analysis
* Through thousands ofapplications in
the past, it is not yet known to have led to
catastrophic adverse effects in humans.
Although the RfD/ADI/Safety Factor
approach is widely used in quantitative risk
assessment, the RfD approach has several
potential limitations. By definition, the RfD
approach uses only the NOAEL/LOAEL
from the data set, and the NOAEL/LOAEL
must be one ofthe doses used in the experi-
ment. It is, therefore, possible that the num-
ber and spacing ofdoses in a study could
affect the dose eventually selected as the
NOAEL. As shown by Kimmel (17), a
NOAEL couldvaryby a factor of3 depend-
ing on the doses used in the experiment.
A potential problem with the RfD
approach is that itdoes not take into account
the shape ofthe dose response curve. Crump
(18) described an experiment in which a
steep dose-response curve resulted in a
NOAEL well below that from an experi-
ment having a dose-response curve with a
shallower slope. Thus the RfD procedure
could result in a more conservative estimate
ofrisk for a chemical with a steeper slope,
even though the steeper slope may indicate
less interindividual variability in response.
The RfD approach also does not take
into account the statistical uncertainties in
determining the NOAEL from the experi-
ment. For example, using a larger number
ofsubjects per group increases the power of
the experiment to detect an effect with
statistical significance at a lower dose.
Therefore, using larger groups ofanimals
would tend to lead to a lower RfD.
Similarly, measures having an inherently
high baseline incident of a toxic effect
could result in higher RfDs than measures
that have a lower baseline effect incidents.
The RfD also makes the assumption
that there is no increase in the incidence of
toxicity over background at exposure levels
at or below the RfD. It does not, therefore,
provide for a procedure to determine risk at
anyother dose. This is particularly problem-
atic ifit is desired to assess a) the increase in
risk that may be present ifexposure occurs
slightly above the RfD, or b) the confidence
that a decision maker should place in the
estimate that risk (incidence ofeffect) will
be below specific numerical targets (or,
conversely, the degree of uncertainty that
might exist that risk might be above
desired target levels).
There is at present no distinctive treat-
ment of neurobehavioral effects in this
process. Developmental effects are sometime
given an extra factor although there is no
general policy. For the long-term future
development ofneurobehavioral toxicology
and decision making, the simple uncertainty
factor approach has a number ofother dis-
advantages (19):
* No one knows how protective the
RfD really is, either in general or in specific
cases. What fraction ofthe diverse human
population can be expected to experience
adverse effects when exposed at the level
calculated to be acceptable under the for-
mula? In general, there may be some finite
fraction ofindividuals who, because ofdis-
ease or other causes, are marginal for bio-
logical functions affected by the chemical
and who may be pushed beyond a func-
tional threshold for an adverse effect by a
small finite dose of the chemical. For
example, for healthy workers there may
indeed be a functional reserve capacity for
oxygen delivery to the myocardium and
hence a finite tolerance for a small impair-
ment ofoxygen-delivering capacity for the
blood due to carbon monoxide. However,
for a worker who has just begun to experi-
ence a myocardial infarction, oxygen deliv-
ery to portions of the myocardium is
known to be seriously compromised, and it
is possible that a small difference in oxygen
delivery capacity due to a modest blood
carboxyhemoglobin concentration could
prove the difference between life and death
for portions of the heart muscle that are
suddenly forced to rely on collateral arterial
vessels for oxygen supply
* The RfD procedure incorporates one
specific social-policy standard for setting
acceptable levels without making clear
where the technical analysis leaves offand
the policy/value analysis begins. Just how
much risk ofwhat degree of response in
what proportion of people can we say is
how unlikely? Is there no difference
among different regulatory contexts and
or different types of end points in the
procedure that should be used to deter-
mine the level of exposure that is safe
enough to permit?
* There is no defined or obvious way to
incorporate newer types ofrelevant data on
human interindividual differences in
- Rates ofuptake/absorption for a con-
stant environmental exposure (exposure
variability)
- Rates of activating or detoxifying
metabolism and excretion, producing dif-
ferences in the concentration x time of
active metabolites per unit of absorbed
dose at the site of toxic action (pharmaco-
kinetic variability)
- Differential risk ofresponse (response
variability) for a given concentration x
time of active metabolites at the site of
toxic action.
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Table 2. Preliminary estimates of interindividual variability in various parameters likely to be related to suscepti-
bility to different kinds of effects/chemicals.a
Width of the 90% rangebfor
chemicals/tests with greater
Width of the 90% rangebfor interindividual variability than
Parameter and parameter class an average chemical or test 95% of all others examined
Systemic pharmacokinetic parametersc
Half-life for elimination (by metabolism
and/or excretion) 2.3-fold 5.8-fold
Maximum blood concentration
(after a single dose) 2.3-fold 11-fold
Area under a concentration-
time curve (AUC) 3.0-fold 8.1-fold
Preliminary estimates of overall variability in sensitivity for neurotoxic risks
Death from agents metabolized by
plasma cholinesterase 5.5-foldd Not available
Death from parathion
(metabolized by paroxonase) 12-foldd Not available
Effects of methylmercury poisoning in
adults (Bend points) 12-folde 78-folde
Fetal/developmental effects of methylmercury
poisoning (5 end points) Approx. 460b Approx. 10,000 foldb
"Adapted from Ashford et al. (20). bThe numbers are the ratios of the value of each parameter for the 95th
percentile individual to the value of the parameter for the 5th percentile individual (see Figure 1 for illustration),
based on the assumption that the values of the parameter are lognormally distributed (that is, the logarithms of
the parameter values are normally distributed). cData from Hattis et al. (21). dData from Hattis et al. (22). "Data
from the National Academy of Sciences (19). fData from Hattis and Silver (23) and Hattis (24). Caveat:
Imperfection of the dosimeter used here (maternal hair mercury) may have led to serious overestimation of the
actual extent of interindividual variability.
Width ofthe 90% range it Table 2
E ~
z
5 ~~~~~~~~~~~5%
Log (toxin elimination rate)
Figure 1. Interindividual variability of toxin elimination
from the body based on the assumption that the loga-
rithms of half-lives for elimination of toxins from the
body are normally distributed.
In particular, it is also likely that the
inability of the uncertainty factor paradigm
(as usually formulated) to incorporate newer
types ofrelevant information into a system-
atic procedure for updating assessments of
health hazards has tended to discourage
both the collection and analysis of poten-
tially important data. One example ofthis is
information on human interindividual vari-
ability in parameters that could affect sus-
ceptibility. Table 2 gives an overview of
preliminary estimates of the extent of
human interindividual variability in sus-
ceptibility for a number of parameters of
potential interest for neurotoxicity risk
assessment. The numbers in both columns
indicate the spread of interindividual vari-
ability observed, expressed as the ratio of a
95th percentile individual value to a 5th
percentile individual value (Figure 1). The
difference between the two columns can be
thought of either as variability among
chemicals tested in the same way (or, in
some cases, different tests for the same
chemicals), or the uncertainty facing an ana-
lyst in assessing the amount ofinterindivid-
ual variability in susceptibility to the
carcinogenic effect of a chemical for which
there are no direct measurements ofhuman
variability. The first column of numbers in
Table 2 relates to median chemicals ana-
lyzed for each effect, or the median of sev-
eral available tests of the same parameter,
such as breathing rates; the second column
represents observations for a 95th percentile
high-variability chemical or test. Such data
are not commonly compiled in this form in
the normal course of risk evaluation for
neurotoxic and other noncancer agents.
AlternativeApproaches for
Development ofMoreQuantitative
Information on Risks-Pros and Cons
Benchmark Dose/Crump. The approach
originally proposed by Crump (18) uses the
bench mark dose (BMD) in place of the
NOAEL to determine the RfD. In that
sense, among the approaches surveyed here,
the BMD makes the least disruption ofcur-
rent approaches for analysis of noncancer
end points. The BMD is defined as the
lower 95% (bound) confidence limit on the
dose corresponding to a particular incidence
of a quantal effect (usually 10 or 5%) in a
dose-response curve calculated by fitting a
mathematical model to the observed data.
The dose-response models used for this
purpose can be ofany ofa number offorms;
those originally recommended by Grump
include the polynomial forms often used for
carcinogenesis risk assessment. As in the case
ofthe RfD approach, uncertainty factors are
applied to the defined benchmark dose to
calculate the benchmark-RfD. It has been
suggested that the BMD provides a com-
mon starting point for applying uncertainty
factors and might result in RfDs that pro-
vide more comparable levels ofprotection
than when NOAELs are used (17).
Advantages of the BMD include the
fact that the approach uses data from the
entire dose-response curve, and the statisti-
cal uncertainties arising from experimental
design (dose spacing, numbers of animals
used, background incidence of effects) all
naturally affect the width ofthe confidence
intervals around the points in the fitted
dose-response relationship and therefore the
degree of conservatism built into the risk
assessment. Unlike the NOAEL approach,
there is no requirement for the BMD to be
one of the experimental doses. The BMD
approach incorporates information on the
shape of the dose-response curve and is
not inconsistent with the previous assump-
tion of a population threshold dose. More
controversially, the BMD also allows for the
estimation ofrisk at given levels ofexposure.
If exposure exceeds the RfD, an upper
bound on the excess risk can be estimated,
and some regulatory decisions can be made
as to whether the potential change repre-
sents an unacceptable risk in a particular
decision making context.
The BMD approach still utilizes uncer-
tainty factors to calculate the RfD. Unlike
the default RfD approach, however, which
uses uncertainty factors of 10 to account
for interspecies variability, less-than-life-
time exposure, and animal-to-human
extrapolation (Table 1), some advocates of
the BMD approach suggest that it should
be used to define limits ofacceptable risk
(i.e., 1/10, 1/100, 1/1000, or 10,000 (25).
Thus, both the default RfD and BMD
approaches rely on relatively arbitrary units
of 10 for uncertainty factors that are used
to calculate the RfD.
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Gaylor/Slikker. Gaylor and Slikker
(26) have proposed an approach to risk
assessment that is based on the control vari-
ability ofthe measure of interest. In their
preliminary presentation ofthe method, an
example in which monkeys were treated
with MDMA was used to demonstrate the
risks ofdecreasing serotonin (5HT) levels.
In that example, the normal variation in
5HT was determined from a control sam-
ple, and a level of 3 standard deviations
(SD) was used as a metric to define an
abnormal level of 5HT. The effects ofsev-
eral treatments with different dose levels of
MDMA served to establish a dose-response
function for the relationship between the
decrease in 5HT as a function ofMDMA
treatment. On this dose-response function,
a dose was chosen as one for which risks
would be determined. The assumption that
variation in levels of 5HT after this
treatment was applied to the mean effect,
obtained from the function, and the over-
lap of this distribution with the level at
which 3SD in the control data provided an
indication ofthe proportion ofthe popula-
tion expected to be affected abnormally at
that dose. The method is easily adapted to
assessing the increase in risk posed by
progressively smaller doses by comparing
similar distributions ofeffect, until the addi-
tional area (over background) under these
distribution curves beyond the 3 SD cutoff
is as small as 1/100 or 1/1000.
The method has not been used exten-
sively to fully evaluate potential concerns.
One concern that has been voiced, how-
ever, is that the assumption that variability
in effect exhibited at an interpolated dose
should be measured rather than assumed.
The use ofassumed variability measures at
very low doses may also preclude the ability
to realistically predict effects at low doses. A
clear advantage of the method is that it
unambiguously defines an abnormal effect
(3 SD), and as such may be useful in adapt-
ing risk assessment procedures to continu-
ous variables that do not span a range that
can be characterized by traditional scales.
Dews/Glowa. Dews (27) proposed a
different method of assessing risks. In his
approach, effects in individual animals are
obtained such that a small effect can be
defined in each subject. Typically, this
was done by establishing a dose-effect
function for several different subjects,
using the simplest model that could be
used to describe the function (typically a
linear function was fitted). From each
function a small effect, similar to that
proposed by Crump (18) was chosen and
the mean and distribution of the effect
was characterized.
Dews assumed that these individual dif-
ferences in effect (or a log transformation)
would be normally distributed. By making
this assumption, it was easy to compare the
distribution ofexpected effects using nor-
mal curve statistics (i.e. the probability of
an effect in the population is distributed as
a Z-score). By selecting a probability of
interest (e.g., 1/10, 1/100, or 1/1000), the
intercept ofthat point on the distribution
with the abscissa specifies the dose at which
that incidence ofeffect is expected.
The method has the advantage of
being simple and relatively independent of
the type of function chosen to represent
the individual dose-effect functions. It also
is one of the few methods that actually
determines a population-sensitivity mea-
sure and uses it for risk assessment. The
assumption that the doses producing
specific amounts ofeffects are normally or
lognormally distributed is an additional
benefit, because a great deal is known
about the normal curve, in contrast to the
fact that we know very little about the
shape of the dose-effect function at low
levels. The level chosen is somewhat arbi-
trary, but 10% usually lies within the
directly measurable portion ofthe curve.
A distinct disadvantage ofthe approach
originally described by Dews (27) is that it
may not be applicable to all types ofdata.
For example, agents with irreversible
effects, or developmental or chronic stud-
ies, rarely provide single subject data.
Recently Bogdan et al. (unpublished data)
described a method that remedies this
deficit. In this approach, group design
dose-effect data are obtained, i.e., a control
group is dosed with vehicle and several
dose groups are given a single dose each.
From these data an iterative computer pro-
gram generates all possible lines that can be
fit to all possible combinations ofone point
per dose curve. Thus, a study with two ani-
mals per dose and three doses would gener-
ate eight possible combinations. The effects
can be calculated in absolute terms or as
percentage ofthe control group.
Probit and Logit Tolerance Distri-
bution Models. When the available data on
effects are quantal (plus/minus; cases/non-
cases) and the primary issue foranalysis is the
spread ofinterindividual variability in a pop-
ulation, log probit and logit dose-response
functions may be appropriate. Both the log
probit and the logit are tolerance distribu-
tion models: they are based on the assump-
tion that the effect in question is produced
in different individuals when individual
threshold doses are exceeded. In the case of
the log probit model, these threshold doses
are assumed to be lognormallydistributed in
the exposed population (that is, the loga-
rithms ofthe threshold doses for individual
people/animals are assumed to have a nor-
mal gaussian distribution). In the case ofthe
logit model, the population distribution of
thresholds is assumed to correspond to a
logistic function.
In practice there is very little difference
in the dose response projections made
using these two models for effect inci-
dences between 1 and 99%. The logistic
model has slightly broader tails and there-
fore makes somewhat larger predictions of
low dose risks when projections are made
from high-dose observations. A report by
the U.S. National Academy of Sciences
(19) has a comparison oflow dose predic-
tions of risks from fetal developmental
exposure to methylmercury using the logit
(28) and log probit models, as applied to
the human data from the mass poisoning
episode in Iraq (29). At a dose predicted by
the logit model to produce a 0.5% inci-
dence of late walking in gestationally
exposed offspring, the probit model predic-
tion was for a0.25% incidence ofthe effect.
The logit model tends to be favored by
statistically oriented workers because of its
computational convenience in fitting data.
The traditional maximum likelihood pro-
cedure ofFinney (30) often used to fit the
log probit function, is by contrast relatively
cumbersome, although automated routines
are available. The rationales advanced by
advocates ofthe probit model include a) at
least a vague mechanistic foundation (a log-
normal distribution ofthresholds would be
expected to be produced ifthere were sev-
eral factors that contributed to interindivid-
ual differences in sensitivity and if these
factors tend to act multiplicatively in deter-
mining individual thresholds); and b) a long
history of prior usage in the traditional
analysis ofanimal dose-response data (most
notably in the calculation ofLD50 values).
For example, Gaddum (31) described one
ofthe first quantitative approaches to risk
assessment in his early attempt to develop a
method to establish safe doses. While a
number ofparameters of-the dose-effect
data were used, the approach was essentially
to establish a safe dose as one calculated to
be six standard deviations below an easily
observable effect (e.g., LD50). Ofnote, it set
the occasion for displacement in the dose
dimension based on variability established in
the effect dimension and, more importantly,
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used a fair portion of the available
dose-effect information. However, it was a
point estimate that provided no indication
ofthis uncertainty in the risk (safe) figure.
Although both of these models are
based on an assumption that effects are
produced in different individuals when
their personal thresholds are exceeded, in
contrast to the RfD procedure, there is no
necessary assumption of a population
threshold-a dose so low as to be below
the threshold of every single person in a
large mixed population. However, particu-
larly for the probit model, expected effect
incidences decline to very low levels after
doses are reduced below several SDs from
the population median threshold.
Finally, as implied at the start of this
subsection, the assumptions underlying the
probit and logit models are rarely compati-
ble with the mechanisms that produce the
kind of continuous data common in
describing many neurotoxicological end
points. An exceptional case ofthe applica-
tion of the probit model to continuous
(nonquantal) data on the depression of
dopamine concentrations in specific brain
regions by MPTP is based on the assump-
tion that the measured reductions in
dopamine levels may reflect the amount of
killing ofrelevant cells by MPTP (24). Such
killing could be expected to result from the
exceedance ofindividual thresholds, where
the individuals in this case are individual
cells in a mixed population ofneurons.
The basic idea that at some level there
should often be thresholds for individual
responses for many types ofadverse effects
does have some mechanistic justification.
The dominant paradigm oftraditional toxi-
cology and pharmacology views biological
systems as complex interacting webs of
processes so designed that the perturbation
ofany one parameter automatically gives rise
to countervailing influences that tend to
keep the system within normal limits (32).
Given that some effects are produced by
individual threshold processes, the probit
model offers a direct opportunity to assess
the spread ofthe population distribution of
the thresholds. The estimated SD of the
population distribution ofthe logarithms of
the thresholds is the reciprocal ofthe pro-
bit slope in conventional plots ofthe probit
of response versus log dose (24). A caveat
here is that, when applied to animal data,
this SD refers to the animal population. It is
likely that relatively genetically uniform
strains ofanimals, raised under controlled
laboratory conditions, may often have less
interindividual variability than outbred
humans exposed at different ages and with
different histories ofother exposures, nutri-
tion, etc. Because ofthis, there may be a
need to adjust expectations ofinterindivid-
ual variability in humans when using animal
data to project human risks with tolerance
distribution models.
Quantitative Mechanistic Modeling.
The interplay between mathematical theory
and experimental neurotoxicology could be
greatly enriched through efforts to build
more mechanistic understanding into the
mathematical models used to represent neu-
robehavioral changes. A paper elsewhere in
this volume (24) emphasizes thefollowing:
a) The mathematical form for a
dose-time-response model is ideallynotjust
a convenience for summarizing or fitting a
particular data set-it represents a hypothe-
sis. The more this hypothesis reflects a
mechanistically sophisticated view of the
likely reality, the more it can lead to poten-
tially informative validating/invalidating
types of predictions about the results of
real experiments, and (in the long run) rea-
sonably credible predictions outside the
range ofpotential direct observation ...
b) Models are simplifications ofreality.
They are intended to represent the likely
behavior ofa complex system ofinterest by
focusing on the behavior of a few salient
features or components of the system. If
the features included in the model are the
prime determinants ofthe behavior ofthe
system (that is, ifother variables that could
also affect the system are relatively constant
or relatively unimportant) then there is a
hope that the model will reasonably accu-
rately represent the behavior ofthe system
over a particular domain ofconditions.
Some features ofneurotoxic effects that
are amenable to quantitative dynamic
modeling at the present time are
* The ability to establish definitive rela-
tionships between external dose and the
internal dose-time profile at the presumed
site(s) ofaction for some chemicals. This is
best done using the well-developed para-
digm ofphysiologically based pharmacoki-
netic modeling (33,34), which has been
extensively used in carcinogenesis risk assess-
ment in recent years (35). The importance
ofgood active site dosimetry is to separate
nonlinearities ofpharmacokinetic origin
from nonlinearities arising from fundamen-
tal neurotoxic processes in the chain of
events leading from external exposure to the
production ofneurobehavioral responses
* The familiar tools of Michaelis-
Menten enzyme kinetics are readily adapt-
able to elucidating the dose response
relationships for both saturable transport
processes and the inhibition ofenzymes that
are important for the survival and function-
ingofcells in the nervous system (36).
* The accumulation and repair of
reversible neurotoxic damage can be pre-
sented in pharmacodynamic models in
some cases (37).
Reference (24) includes some more
exploratory uses ofmechanistic models for
the central processes involved in neurotoxi-
city including a) chronic accumulation of
irreversible damage via the loss ofneuronal
cells; b) the use ofintermediate biomarkers
along the causal pathway to neural dys-
function to aid in dose-response and popu-
lation effects modeling (38); and c) the
implications of the structural features of
neuronal systems (e.g., redundancy, series
arrangement ofcells performing functions,
plasticity) for the relationships between
dose-response relationships for the inhibi-
tion ofneurobehavioral function and dose
response relationships for the inhibition of
individual neurons.
Recommendationsfor
Assessing New or Old Agents
with Good Data
The previous sections have described the
generic advantages and disadvantages of
several quantitative risk assessment method-
ologies. The current section will attempt to
apply these models to various types ofdata
sets that may be encountered in the risk
assessment process. In this section it is
assumed that some hazard identification has
already occurred and that the risk assessor is
presented with a set ofdata requiring a risk
assessment decision. A preliminary assess-
ment of the data set has indicated that a
neurobehavioral effect is the critical end
point and quantitative risk assessment
shouldproceed using these data.
Typically the first step in the process is
to identify the relevant toxicity studies
and the supporting data that can be used
to select and modify the best approach for
the generation or application of a dose-
effect function. The most usable types of
dose-effect functions are those that clearly
delineate control variability and assess a
sufficient number ofdoses to a) establish a
NOEL/NOAEL or a benchmark dose, b)
characterize the slope of the dose-effect
function; and, ideally, c) relate to potentially
testable theories of toxic mechanism. The
application ofrisk assessment methodologies
clearly depends on the type and amount of
data available. The simple demonstration
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ofan effect may not be sufficient to assess
risks quantitatively.
Examples
As with the RfD approach, several features
of the type of end point used for assess-
ment, the nature of the control data, the
experimental design (e.g., number ofdoses,
times), variability in effect, and mechanis-
tic information can contribute to the risk
assessment process using quantitative meth-
ods. In an effort to present the role ofthese
variables and the possible use ofthe differ-
ent quantitative methods under different
conditions, the following representative
examples ofdatasets are presented:
a) A developmental study was con-
ducted in which groups of pregnant rats
were treated with a penicillin derivative
(100, 500, and 2000 mg/kg, po) and a
control group was treated with vehicle dur-
ing days 6 to 15 of pregnancy. A typical
battery of developmental end points was
assessed, and changes in these variables
were used as a covariate in the determina-
tion ofsignificant neurobehavioral effects.
In this study a significant change in activity
was found at the highest dose as deter-
mined using concurrent and historical con-
trol levels ofactivity. The dose had no toxic
effects on the mother. Additional informa-
tion came from a placental transfer study
that established embryo-fetal exposure over
the whole dose-range studied and from a
pharmacokinetic study in pregnant animals
that showed a linear increase in plasma lev-
els up to the highest dose.
This developmental study provided
good dose-effect data and a range of nor-
mal control data, allowing each of the
methods to be applied. An RfD could be
calculated based on the next-to-highest dose
being chosen as a NOAEL, as it did not
produce observable effects. This would,
under the current example, produce an
RfD that was considerably below therapeu-
tic levels, indicating that at therapeutic lev-
els some risk was present. The calculation of
a risk figure by each ofthe other methods
would also likely point to a dose of peni-
cillin that might be expected to exhibit
developmental risk at therapeutic levels. Use
ofthe probit model for this purpose would
be marginal, however, since it would require
an assumption about the probit slope, and
there is only one positive dose.
Risk assessment for medicinal products
rarely involves the definition ofa dose that
is regarded as virtually safe. The ultimate
requirement is that the minimal therapeu-
tic dose (concentration of active substance
in most cases) doses not pose an unreason-
able risk to the patients in relation to the
anticipated therapeutic benefits. Preclinical
studies, although generally referred to as
safety testing, will be directed, therefore, at
detecting and characterizing adverse effects
with the aim ofenabling the investigators
to assess/quantify risks at therapeutic dose
levels. During the preclinical phase of
pharmaceutical testing the key elements of
risk assessment for neurobehavioral/neuro-
toxic end points involve judging the rele-
vance offindings to humans, considering
the biological properties of the animal
models used.
b) In another study, a collection ofcase
reports in which an increased incidence of
neurological symptoms associated with
eosinia myalgia were noted in several coun-
tries where a tainted tryptophan product
had been sold. Because this data set
involved simply the observation that an
increased incidence ofeffect was seen in an
exposed population and neither dose-effect
nor control data were available, none ofthe
methods are applicable; more data would
be required.
c) A case-control epidemiological study
involved subjects with neurotoxic signs sus-
pected to have resulted from deltamethrin
(pyrethroid insecticide) exposure. Subjects
matched for age, living standards, and other
health and socioeconomic factors were used
as controls. Effects were determined by
clinical assessment, exposure was deter-
mined byquestionnaire.
Because individuals in the control
group in case-control studies are poten-
tially exposed (yet unaffected) and it may
be difficult to establish dose-effects in the
exposed group, this is a potentially difficult
design to use for risk assessment. However,
if a stratified analysis reveals that effects
increased over a range ofexposures it may
be possible to apply the benchmark meth-
ods or other dose-time-response models,
ideally with corrections for the biasing
effects of inaccuracies in the estimation of
exposures (23).
d) In an occupational workplace study
blood levels of toluene were determined
directly after testing using an automated
neurotoxicology test battery. Populations
from several sites at the factory were tested,
providing several ranges of level and
including a nonexposed control. The per-
formance deficits on the battery were posi-
tively correlated with hippuric acid level.
This workplace study would provide
good effect and dose data, good characteri-
zation ofhuman pharmacokinetics, and at
least some preliminary hypothesis genera-
tion for neurotoxic mechanisms, allowing
each ofthe methods to be used.
e) A dose-response study in rats was
designed to characterize acute effects of
alprazolam on activity. Rats were placed in
activity monitors once daily until stable
baselines were established. Animals were
given vehicle and different doses on sepa-
rate widely spaced occasions until individ-
ual dose-effect curves were established for
10 animals. Control variability was approx-
imately 10%. Activity was unaffected at
the lowest dose tested and abolished at the
highest dose tested.
This dose-response study would pro-
vide good effect and dose data, allowing
each of the methods to be used. Since
individual animal variability is directly
assessed in this study, the method ofDews
provides the most direct measures of risk.
Probit and mechanistic analyses may also
be possible.
f) Another dose-response study in rats
was designed to characterize acute effects of
MPTP on activity. Four groups ofsix rats
each were treated with vehicle or with one
of three doses of MPTP and tested three
days later. Levels ofactivity were 200 pho-
tocell counts/15 min session in the control
group, and they progressively decreased in
a dose-related manner in each ofthe exper-
imental groups. Variability was essentially
the same in each ofthe groups.
This type ofstudy would provide good
effect and dose data, allowing each of the
methods to be used. Since variability in
effect was comparable between control and
dosed groups, the method ofGaylor/Slikker
could be applied without reservation.
Because some aspects ofthe mechanism of
action of MPTP have been characterized
(e.g., loss ofneurons relevant to some func-
tions) a quantitative mechanistic analysis
may also be possible.
g) Finally one study assesses the effects
ofchronic (90-day) exposure to n-hexane
(0, 100, 300, 1000 ppm) using a functional
observational battery (FOB) in mice. The
battery was assessed twice-on the second
day and the second week after the termina-
tion ofexposure. Effects were noted on 10
end points 2 days after the termination of
exposure in the high-dose group. These
effects were not apparent 2 weeks after
exposure ended.
This studywould provide an initial indi-
cation ofdose-effect that dissipated with
retesting. Quantitative mechanistic analysis
may be possible ifsufficient data are avail-
able on the dynamics and dose-response of
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Table 3. Applicability of risk assessment methods to the exemplary data sets.
Example a b c d e f g
Method
RfD + + - + + + +
BMD + - + + + + +
Dews + - - + + + +
Gaylor + - _ + + + +
Probit/logit - -+? + + + +
Causal/ mechanistic - - - + +? + +
+ Denotes applicable. -Denotes notapplicable. ? Denotes possibly applicable butquestionable.
either the appearance or the disappearance
ofthe functional changes.
It is obvious that each ofthese quantita-
tive risk assessment methods can be used
under various conditions with different
types ofdata and, also, some methods are
inappropriate with some types ofdata. The
applicability ofthe different models to the
different data sets as described is summa-
rized in Table 3. When faced with these
types of choices, the risk assessor may be
compelled to chose a method with which
he/she is most familiar or one that pro-
duces the most conservative risk figure.
Since few studies have directly compared
these different methods using the same
data set, such choices may be less than
ideal. Rather, it may be more instructive to
compare the figures produced by each to
understand the methods better.
With the possible exception of the
probit and mechanistic models, virtually
none of the methods conceived after the
development ofthe RfD actively contribute
to the exploration of the effectiveness or
necessity of uncertainty factors. Crump
(18) and Gaylor and Slikker (26) explicitly
state that uncertainty factors have to be
added to the number produced by their
methods. Dews (27) discusses the possibil-
ity offinding species more and less suscep-
tible than humans and interpolating rather
than extrapolating for interspecies differ-
ences. Many of these methods, especially
that of Dews (27), explicitly measure
intraindividual variability, which may
discount the need for including that factor.
Several other studies have discussed various
assumptions related to inter-species uncer-
tainty factors [e.g., Rees and Glowa (39);
Rees and Hattis (32)] concluding that
these factors can be measured rather than
assumed. Acute-to-chronic uncertainty fac-
tors may also apply for some agents and
not others-no one has ever accomplished
a full-term lifetime study to approach this
question directly. Thus, for each of the
examples provided below, one or more
uncertainty factors could be applied. The
risk assessor must recognize that the appli-
cation ofthese factors may have consider-
ably more weight on the numerical
outcome than the differences between
these methods discussed.
Emerging lSsues
There are a number ofother issues impor-
tant for neurobehavioral toxicity that should
be considered by the risk assessor in evaluat-
ingdatasets.
Reversible andIrreversibk Changes.
One issue ofconcern to the risk assessor is
the observation that a toxicant-induced
change in behavior might dissipate soon
after cessation ofdosing or appear to lessen
during the course of repeated exposure.
Persistent changes in neurobehavioral mea-
sures should be always be viewed with a
high degree of concern, but it does not
always follow that reversible changes should
be discounted or ignored in the risk assess-
ment process. It is important to realize that
the nervous system has a combination of
special features not found in other organ
systems. For example, the nervous system is
composed ofa number ofdifferent types of
cells, each having its own functions and vul-
nerabilities. After a certain age, the process
ofneurogenesis ceases, and toxic damage to
the brain or spinal cord could result in per-
manent loss ofnerve cells. Ifthe loss is con-
centrated in one of the nervous system's
functional subsystems, the outcome could
be devastating. One ofthe key features of
the nervous system is that it has the capabil-
ity to compensate for loss offunction fol-
lowing damage and this compensation
could mask the presence ofnervous system
damage. In the peripheral nervous system, if
the cell bodies are not damaged, the axons
have the ability to regenerate and attempt to
reach their original target site. Therefore,
eventual return ofsensation and function
might gradually occur after toxicant expo-
sure. Residual damage to the peripheral
nerve might still be present, however, and
detected only by using tests capable of
detecting relatively subtle neurobehavioral
deficits. Neurons in the central nervous sys-
tem also have the ability to regenerate, but
they have a much more difficult task in
reaching their original targets due to both
the presence ofscar tissue formed by prolif-
erating glia and to the increased complexity
ofthe connections in the central nervous sys-
tem. Loss ofneurons in the central nervous
system isgenerallyregarded as permanent.
At the present time, there is limited
understanding about how to calculate or
correct for compensation or reversibility in
neurotoxicity risk assessment. Biologically
based dose response models are being devel-
oped to assist the risk assessor in evaluating
such changes following exposure to neuro-
toxic agents (40).
Multiple End Points in Neuro-
behavioralStudies. There are several types
ofneurobehavioral effects that can be mea-
sured following exposure to toxic agents
(8,41). In the case ofhumans, there are a
number of examiner-administered and
paper and pencil tests used to assess sensory,
motor, cognitive, affective, and personality
states or traits. Human neurobehavioral
toxicology has also adopted a number of
techniques from neurology and neuropsy-
chology to assess nervous system impair-
ment. Likewise, behavioral procedures from
experimental psychology, behavioral phar-
macology, and neurology are often used to
detect and characterize neurobehavioral
toxicity in animals. Frequently, neurobehav-
ioral assessments use a number ofmeasures
in a battery oftests. Such batteries can con-
sist ofdifferent kinds ofdata induding con-
tinuous, categorical, and rank data. The
risk assessor must be concerned about the
different levels ofpower inherent in each of
the different types of test measures since
that could significantly affect the end point
selected as the critical effect in the quanti-
tative risk assessment. Furthermore, the
risk assessor should be aware that the use of
multiple end points in the same animals or
subjects might need to be corrected statisti-
cally to avoid false positives.
Susceptible Popuationm. In general, we
are all at risk ofbeing adversely affected by
exposure to neurotoxic agents. Individuals
of certain age groups, health states, and
occupations, however, may be at a greater
level ofrisk. It is widely accepted that the
developing nervous system is differentially
sensitive to chemical insult. During the
developing period, the nervous system is
actively growing and establishing the neces-
sary connectivity for normal functioning
during adulthood. Protective systems such
as the blood-brain barrieranddetoxification
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mechanisms such as certain metabolic
enzymes may not be present during critical
periods ofdevelopment. Therefore, expo-
sure to chemicals during development could
result in a range ofeffects that would not be
present or detectable in the adult organism.
It is now evident that the presence of
developmental neurotoxicity may depend
on the specific periods ofnervous system
development (42). In addition, the results
of early developmental exposure may
become evident only as the nervous system
matures and ages. With aging, the level of
risk for a number ofhealth-related factors
increases and it is possible that the risk for
toxic insult to the nervous system may also
increase. It has been hypothesized that the
aging nervous system may have a decreased
ability to compensate for toxic insults and
that exposure to neurotoxicity could
increase the rate ofage-related neuronal cell
loss (43). Examples ofother possible sus-
ceptible populations include individuals
having neurodegenerative disorders such as
Parkinson's or Alzheimer's Disease, those
with nutritional deficiencies and certain
ethnic groups. Gender-dependent responses
to neurotoxicants have also been noted.
Most current standard risk-assessment
methodologies attempt to correct for dif-
ferences in susceptible populations by
using an uncertainty factor for within pop-
ulation variability. Whether a factor of 10
or less is sufficient to protect against the
differential sensitivity ofdifferent groups is
not known, and the risk assessor should be
aware that qualitative, as well as quantita-
tive, differences could affect the risk assess-
ment process.
Shape ofthe Dose-Response Curve.
Many ofthe methods used in quantitative
risk assessment assume a linear or sigmoidal
monotonically increasing dose-response
curve. However, inverted U-shaped dose-
response curves are sometimes observed in
neurobehavioral studies. For example, it is
sometimes observed that an agent will
increase the frequency ofa response, such as
motor activity or schedule-controlled
behavior, at low doses while decreasing
responses at higher doses. In such cases, it
may be difficult to determine which part of
the dose-response curve should be used in
quantitative risk assessment. The risk asses-
sor should be aware that different critical
effects could be obtained depending on the
arm of the dose-response curve which is
selected and that some quantitative
methodologies will not be appropriate for
such data.
During the process ofrisk recognition
and from attempts to test for risk routinely
to prevent or regulate exposure to neuro-
toxicants, we appear to have discovered
valuable information about the behavior of
investigators and risk assessors. In brief,
there appears to be less interaction than
would be desirable.
Summary
The concept ofrisk as it relates to neurobe-
havioral toxicology has evolved over time.
Guidelines for how to test chemicals for
neurotoxicity are being followed by risk
assessment guidelines. The focus in research
has shifted from qualitative risk assessment,
i.e., hazard identification, to quantitative
risk assessment, i.e., how to predict risk
based on available data.
Several quantitative models of risk
assessment have been proposed during the
last several years. The traditional default
approach, i.e., the RfD, is based on the
allowable daily intake hypothesis proposed
over 40 years ago. Risk assessors are now
confronted with a wide array ofrisk assess-
ment methodologies, each having their own
advantages and disadvantages, depending
upon the experimental design and charac-
teristics ofthe dataset.
Current risk assessments using neurobe-
havioral data face several problems that
could confound the interpretations of the
result, including reversibility ofeffect, sus-
ceptible populations, multiple end points,
and the shape of the dose-effect curve.
Clearly, the state-of-the science for quanti-
tative risk assessment of neurotoxicity is
evolving and can be improved only through
additional research.
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